The abstracts will be available on the ASCO® website on May 22, 2025 at 5:00 p.m. ET. The full presentation will be available on the Merus website at the start of the session.

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

The company has 51 applications pending at various stages in the approval process. ETMarkets.com ISB 2001, a trispecific antibody, which aims to treat multiple myeloma, a type of blood cancer, may ...

a bispecific antibody. This indicates that trispecific antibodies may provide a more thorough approach to combating disease by activating additional pathways or immune responses. The capability to ...

Building on this foundation, bispecific and trispecific antibodies have emerged ... with the bispecific antibody market estimated at around US$ 12 billion in 2024. Projections from KuicK Research ...

Building on this foundation, bispecific and trispecific antibodies have emerged as innovative biologics aimed at ... The success of these agents is evident in market valuations, with the bispecific ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...